Noncompaction cardiomyopathy medical therapy: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Antiplatelet Therapy== | ==Antiplatelet Therapy== | ||
Given the risk of [[embolization]], | Given the risk of [[embolization]], all patients with NCC are generally treated with prophylactic [[aspirin]]. | ||
==Beta Blockade== | ==Beta Blockade== | ||
Revision as of 12:06, 6 August 2011
|
Noncompaction Cardiomyopathy Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Noncompaction Cardiomyopathy from other Diseases |
|
Diagnosis |
|
Treatment |
|
Noncompaction cardiomyopathy medical therapy On the Web |
|
Risk calculators and risk factors for Noncompaction cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of ACE inhibitors, beta blockers and aspirin[1].
Antiplatelet Therapy
Given the risk of embolization, all patients with NCC are generally treated with prophylactic aspirin.
Beta Blockade
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk.
Angiotensin Converting Enzyme (ACE) Inhibition
Similar to other cardiomyopathies, ACE inhibitors are indicated given the low cardiac output in these patients.
References
- ↑ Botto, LD. Left ventricular noncompaction. Orphanet encyclopedia. http://www.orpha.net/data/patho/GB/uk-LVNC.pdf